Jupiter Life Line Hospitals profit and loss

Latest FY26

Revenue: ₹1,500cr+18.9% on FY25
EBITDA: ₹343cr+15.7% on FY25
Net profit: ₹199cr+2.9% on FY25
EPS: ₹29.59+0.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Expenses
	1,621	1,500	1,262	1,070	893
	39.4	42.4	28.7	26.0	10.4
	1,660	1,542	1,290	1,095	903
	318	299	233	192	—
	−8.2	−11.9	−2.8	−2.3	−3.7
	287	256	214	190	—
	43.2	32.7	10.6	26.3	42.3
	99.9	87.6	57.0	42.4	38.6
	665	613	520	452	—
	1,405	1,277	1,033	900	772
	359	343	297	238	201
	259	256	240	196	163
Profit
	255	265	258	195	131
	−6.4	0.0	0.0	0.0	—
	249	265	258	195	129
	54.8	63.7	60.4	52.0	51.4
	8.7	2.5	3.8	−33.2	4.4
	63.5	66.2	64.2	18.8	55.8
	185	199	194	177	72.9
	185	199	194	177	—
	1.0	−4.5	−1.2	1.2	—
	186	195	192	178	73.1
	187	194	193	—	—
	0.2	0.2	0.3	0.0	—
Per share
	₹21.59	₹29.59	₹29.47	₹28.65	—
	₹21.59	₹29.59	₹29.47	₹28.65	—
Revenue detail — as filed
	—	0.0	−4.7	0.0	—
Other comprehensive income — detail
	1.0	−4.5	−1.2	—	—
	—	—	−1.6	1.2	—
	−1.9	4.5	−0.4	—	—
	186	194	—	—	—
	0.2	0.2	—	—	—
Per share — as-filed variants
	₹21.59	₹29.59	₹29.47	₹28.65	—
	₹21.59	₹29.59	₹29.47	₹28.65	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,311	1,213	1,031	880	—
	80.9%	80.8%	81.8%	82.3%	—
Adjusted (ex-exceptional items) — derived
	255	265	258	195	131
	−6.4	0.0	0.0	0.0	—
	190	199	194	177	74.2
	₹22.15	₹29.59	₹29.47	₹28.65	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JLHL₹260.10

Jupiter Life Line Hospitals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH KIMS HCG MARKSANS METROPOLIS PARKHOSPS CORONAMcap ₹1,705 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	892.5	1,069.5	1,261.5	1,499.8	1,620.7
Other Income	10.4	26.0	28.7	42.4	39.4
Total Income	903.0	1,095.5	1,290.2	1,542.2	1,660.1
Expenses
+ Purchases of Stock-in-Trade	—	191.8	232.9	299.1	317.5
+ Changes in Inventories	-3.7	-2.3	-2.8	-11.9	-8.2
+ Employee Benefit Expense	—	189.9	214.5	256.3	287.1
+ Finance Costs	42.3	26.3	10.6	32.7	43.2
+ Depreciation & Amortisation	38.6	42.4	57.0	87.6	99.9
+ Other Expenses	—	451.9	520.3	612.9	665.5
Total Expenses	772.1	900.1	1,032.5	1,276.8	1,405.1
EBITDA	201.3	238.2	296.6	343.3	358.7
EBIT	162.8	195.8	239.6	255.6	258.8
Profit
PBT before Exceptional Items	130.9	195.4	257.7	265.3	255.0
+ Exceptional Items	—	0.0	0.0	0.0	-6.4
Pretax Income	128.7	195.4	257.7	265.3	248.6
+ Current Tax	51.4	52.0	60.4	63.7	54.8
+ Deferred Tax	4.4	-33.2	3.8	2.5	8.7
Tax Expense	55.8	18.8	64.2	66.2	63.5
Net Income	72.9	176.6	193.5	199.1	185.1
+ Net Income — Continuing Ops	—	176.6	193.5	199.1	185.1
+ Other Comprehensive Income	—	1.2	-1.2	-4.5	1.0
Total Comprehensive Income	73.1	177.9	192.3	194.6	186.2
Net Income to Common	—	—	193.2	194.4	186.8
Minority Interest	—	0.0	0.3	0.2	0.2
Per Share
Basic EPS	—	28.65	29.47	29.59	21.59
Diluted EPS	—	28.65	29.47	29.59	21.59
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	—	0.0	-4.7	0.0	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-1.2	-4.5	1.0
+ Items NOT to be Reclassified to P&L	—	1.2	-1.6	—	—
+ Tax on Items NOT to be Reclassified	—	—	-0.4	4.5	-1.9
Comprehensive Income — Owners of Parent	—	—	—	194.4	185.9
Comprehensive Income — Non-controlling Interests	—	—	—	0.2	0.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	28.65	29.47	29.59	21.59
Diluted EPS — Continuing Operations	—	28.65	29.47	29.59	21.59
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	—	880.0	1,031.4	1,212.5	1,311.3
Gross Margin %	—	82.28	81.76	80.85	80.91
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	130.9	195.4	257.7	265.3	255.0
− Exceptional Items (reconciliation)	—	0.0	0.0	0.0	-6.4
Net Income Adj (tax-effected)	74.2	176.6	193.5	199.1	189.9
EPS Adj	—	28.65	29.47	29.59	22.15
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	10.00	10.00	10.00	2.00
Paid Up Equity Capital	—	65.6	65.6	65.6	65.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.